Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2016 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago? We need to look for a comparison against the company's own recent past, already real and recurring, and early stage. In the transcript, management discusses CUDC-907 and CA170. For CUDC-907, they mention Phase 1 and Phase 2 trials. They say they have completed enrollment in the monotherapy arm of Phase 1, and they have designed Phase 2 to specifically treat patients with MYC alterations. They expect this patient enrichment to increase probability of success. But is that about deal size? No, it's about clinical trial design. For CA170, they say it's the first orally administered small molecule checkpoint antagonist. They expect it to enter the clinic later this quarter. They talk about the Phase 1 study enrolling patients with advanced solid tumors. No mention of deal sizes. For Erivedge, they mention Roche initiated two clinical studies outside BCC. That's about studies, not deals. The question is about successive engagements of the same kind coming in at progressively larger size. This could be interpreted as clinical trials? But the context is about business deals, orders, contracts, projects, customers, sites, or programs. In a biotech context, it might refer to licensing deals, partnerships, or clinical trial expansions. But the transcript doesn't mention any deals or contracts. It's mostly about clinical progress. Management does not discuss any deals, orders, or contracts. They talk about clinical trials and programs. There is no mention of deal sizes increasing. They don't compare current deals to past deals. They don't mention any new partnerships or licensing agreements. So the answer is NO. We need to be careful: the question says "successive engagements of the same kind" - could that be clinical trials? But the examples given are about deals, orders, contracts, projects, customers, sites, or programs. In a biotech, a "program" might be a drug development program. But they are not landing programs; they are developing them.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.